

Form PTO 1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

DOCKET NO.

9511-114-27 CONT

APPLICANT

Richard J. BUCALA, et al.

FILING DATE

October 27, 2003

LIST OF REFERENCES CITED BY APPLICANT
(Use Several Sheets if Necessary)

JUL 09 2004

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
AB	AA	5,585,479	12/1996	HOKE, et al.	
	AB	6,297,253	10/2001	BUKRINSKY, et al.	
	AC	6,492,428	12/2002	AL-ABED, et al.	
	AD	6,599,938	07/2003	Al-ABED, et al.	
	AE	6,645,493	11/2003	BUCALA, et al.	
	AF	6,030,615	02/2000	BUCALA, et al.	
	AG	6,117,837	09/2000	TRACEY, et al.	
	AH	4,946,778	08/1990	LADNER, et al.	
	AI	4,946,674	08/1990	von EICHHORN, et al.	
	AJ	4,708,937	11/1987	REMOLD	
	AK	4,299,814	11/1981	BRANDT, et al.	
	AL	5,411,882	05/1995	ODINK, et al.	
	AM	4,683,202	07/1987	MULLIS	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	NO
AB	AN	WO 96/15242	05/1996	WIPO		
	AO	WO 96/09389	03/1996	WIPO		
	AP	WO 95/31468	11/1985	WIPO		
	AQ	WO 90/11301	10/1990	WIPO		
	AR	2-219586	09/1990	JAPAN		
	AS	0 162 812	11/1985	EPO		
	AT	230 876	12/1985	GERMANY		

EXAMINER /Amy Bowman/

DATE CONSIDERED 07/2006

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DOCKET NO. 9511-114-27 CONT	SERIAL NO. 10/693,498
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		APPLICANT Richard J. BUCALA, et al.			
		FILING DATE October 27, 2003		GROUP ART UNIT 1645	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)					
AB	BA	Nathan, et al., J. Exp. Med., Vol. 133, pp. 1356-1376, 1971.			
	BB	Churchill, et al., J. Immunol., Vol. 115, pp. 781-785, 1975.			
	BC	McInnes, et al., J. Exp. Med., Vol. 167, pp. 598-611, 1988.			
	BH	Thurman, et al., J. Immunol., Vol. 134, pp. 305-309, 1985.			
	BI	Weiser, et al., Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 7522-7526, 1989.			
	BJ	Weiser, et al., J. Immunol., Vol. 147, pp. 2006-2011, 1991.			
	BK	Weiser, et al., Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 8049-8052, 1992.			
	BL	Cuhna, et al., J. Immunol., Vol. 150, pp. 1908-1912, 1993.			
	BM	Taetle, et al., Cancer Treatment Reports, Vol. 71, pp. 297-304, 1987.			
	BN	Bacher, et al., Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 7849-7854, 1996.			
	BO	Nature, Vol. 256, pp. 495-497, 1975.			
	BP	Kosbor, et al., Immunology Today, Vol. 4, p. 72, 1983.			
	BQ	Cote, et al., Proc. Natl. Acad. Sci., Vol. 80, pp. 2026-2030, 1983.			
	BR	Cole, et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96, 1985.			
	BS	Morrison, et al., Proc. Natl. Acad. Sci., Vol. 81, pp. 6851-6855, 1984.			
	BT	Rojanasakul, "Antisense oligonucleotide therapeutics: drug delivery and targeting", Advanced Drug Delivery Reviews, Vol. 18, pp. 115-131, 1996.			
	BU	Gewirtz, et al., "Facilitating oligonucleotide delivery: Helping antisense deliver on its promise", Proc. Natl. Acad. Sci., Vol. 93, pp. 3161-3163, 1996.			
	BV	Branch, "A good antisense is hard to find", TIBS, Vol. 23, pp. 45-50, 1998.			
	BW	Pozzi, et al., "Human recombinant migration inhibitory factor activates human macrophages to kill tumor cells", Cellular Immunology, Vol. 145, pp. 372-379, 1992.			
	BX	Bennett, et al., Science, Vol. 158, pp. 80-82, 1966.			
	BY	David, et al., Pathology, Vol. 56, pp. 72-77, 1966.			
	BZ	Weiser, et al., J. Immunol., Vol. 126, pp. 1958-1962, 1981.			
EXAMINER		/Amy Bowman/		DATE CONSIDERED 11/07/2006	
*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DOCKET NO. 9511-114-27 CONT	SERIAL NO. 10/693,498
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)				APPLICANT Richard J. BUCALA, et al.	
				FILING DATE October 27, 2003	GROUP ART UNIT 1645
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)					
AB	CA	Neuberger, et al., Nature, Vol. 312, pp. 604-608, 1984.			
	CB	Takeda, et al., Nature, Vol. 314, pp. 452-454, 1985.			
	✓ CC	Huse, et al., Science, Vol. 246, pp. 1275-1281, 1989.			
	CD	Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, N.Y., 1989.			
	✓ CE	Lam, et al., Nature, Vol. 354, pp. 82-84, 1991.			
	✓ CF	Logan, et al., Proc. Natl. Acad. Sci. (USA), Vol. 81, pp. 3655-3659, 1984.			
	CG	Mackett, et al., Proc. Natl. Acad. Sci. (USA), Vol. 79, pp. 7415-7419, 1982.			
	✓ CH	Mackett, et al., J. Virol., Vol. 49, pp. 857-864, 1984.			
	✓ CI	Panicali, et al., Proc. Natl. Acad. Sci., Vol. 79, pp. 4927-4931, 1982.			
	CJ	Uhlmann, et al., "Antisense oligonucleotides: A new therapeutic principle", Chemical Reviews, Vol. 90, No. 4, pp. 543-584, 1990.			
	CK	Stein, et al., Science, Vol. 261, pp. 1004-1012, 1993.			
	CL	Kohler, et al., Nature, Vol. 256, pp. 495-497, 1975.			
	CM	Kaiser, et al., Proc. Natl. Acad. Sci. USA, Vol. 80, pp. 1137-1143, 1983.			
	CN	Peck, J. Immunol. Methods, Vol. 64, pp. 179-187, 1983.			
	CO	Sprung, et al., New Eng. J. Med., Vol. 317, pp. 1137-1143, 1984.			
	CP	Beutler, et al., J. Exp. Med., Vol. 161, pp. 984-995, 1985.			
	CQ	Erne, et al., Biochemistry, Vol. 24, pp. 4263-4265, 1985.			
	CR	Beutler, et al., J. Immunol., Vol. 135, pp. 3972-3977, 1985.			
	CS	Suzuki, et al., Am. J. Physiol., Vol. 250, pp. E470-E474, 1986.			
	CT	Liu, et al., J. Immunol., Vol. 137, pp. 448-455, 1986.			
	CU	Thomas, et al., Cell, Vol. 51, pp. 503-512, 1987.			
	CV	Bone, et al., New Eng. J. Med., Vol. 311, pp. 1137-1141, 1987.			
	CW	Ding, et al., J. Immunol., Vol. 141, pp. 2407-2413, 1988.			
↓	CX	Smith, Science, Vol. 240, pp. 1169-1176, 1988.			
EXAMINER /Amy Bowman/				DATE CONSIDERED 11/07/2006	
*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DOCKET NO. 9511-114-27 CONT	SERIAL NO. 10/693,498
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		APPLICANT Richard J. BUCALA, et al.			
		FILING DATE October 27, 2003		GROUP ART UNIT 1645	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)					
AB	DA	Michie, et al., New Eng. J. Med., Vol. 318, pp. 1481-1486, 1988.			
	DB	Wolpe, et al., J. Exp. Medicine, Vol. 167, pp. 570-581, 1988.			
	DC	Sternberg, et al., Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 2374-2378, 1989.			
	DD	Zuckerman, et al., Eur. J. Immunol., Vol. 19, pp. 301-305, 1989.			
	DF	Buhler, et al., Biotechnology, Vol. 8, pp. 140-143, 1990.			
	DF	Edwards III, et al., Endocrinol., Vol. 128, pp. 986-989, 1991.			
	DG	Dinarello, J. Infect. Dis., Vol. 163, pp. 1177-1184, 1991.			
	DH	Edwards III, et al., Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 2274-2277, 1991.			
	DI	Silverstein, et al., J. Exp. Med., Vol. 173, pp. 357-365, 1991.			
	DJ	Holmes, et al., Science, Vol. 253, pp. 1278-1280, 1991.			
	DK	Fry, et al., Biopolymers, Vol. 32, pp. 649-666, 1992.			
	DL	Sigal, et al., Ann. Rev. Immunol., Vol. 10, pp. 519-560, 1992.			
	DM	Blocki, et al., Nature, Vol. 360, pp. 269-270, 1992.			
	DN	Vassalli, Ann. Rev. Immunol., Vol. 10, pp. 411-452, 1992.			
	DO	Fung-Leung, et al., Cell, Vol. 65, pp. 443-449, 1991.			
	DP	Lanahan, et al., Mol. Cell Biol., Vol. 12, pp. 3919-3929, 1992.			
	DO	Sherry, et al., Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 3511-3515, 1992.			
	DR	Bernhagen, et al., J. Cell Biochem. Supplement 178, Abstract E306, 1993.			
	DS	Wistow, et al., Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 1272-1275, 1993.			
	DT	Bernhagen, et al., Nature, Vol. 365, pp. 756-759, 1993.			
	DU	Mikayama et al., Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 10056-10060, 1993.			
	DV	Nathan, et al., J. Exp. Med., Vol. 137, pp. 275-288, 1973./			
	DW	Nathanson, et al., Annals of Internal Medicine, Vol. 120, pp. 771-783, 1994.			
	DX	The Merck Manual of Diagnosis and Therapy, Berkow, Editor-in-Chief, Merck Research Laboratories, Publisher, Sixteenth Edition, pp. 318-319, 338-388, and 1305-1311, 1992.			
	DY	Immunology, Kuby, Freeman and Co., Publisher, p. 266, 1992.			
EXAMINER		/Amy Bowman/		DATE CONSIDERED 11/07/2006	
*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DOCKET NO. 9511-114-27 CONT		SERIAL NO. 10/693,498	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)				APPLICANT Richard J. BUCALA, et al.			
				FILING DATE October 27, 2003		GROUP ART UNIT 1645	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
AB	AA	2003/0212020	11/13/03	Murray, et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION YES NO	
	AK						
	AL						
	AM						
	AN						
	AO						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AP						
	AQ						
	AR						
	AS						
EXAMINER /Amy Bowman/				DATE CONSIDERED 11/07/2006			
*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							